Sangamo Therapeutics Files Q1 2025 10-Q Report
Ticker: SGMO · Form: 10-Q · Filed: May 12, 2025 · CIK: 1001233
| Field | Detail |
|---|---|
| Company | Sangamo Therapeutics, Inc (SGMO) |
| Form Type | 10-Q |
| Filed Date | May 12, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
Sangamo Therapeutics filed its Q1 2025 10-Q. Check financials.
AI Summary
Sangamo Therapeutics, Inc. filed its quarterly report for the period ending March 31, 2025. The company's financial statements and disclosures are presented in this 10-Q filing. Specific financial figures and operational details for the first quarter of 2025 are included.
Why It Matters
This filing provides investors and stakeholders with the latest financial performance and operational updates for Sangamo Therapeutics, crucial for assessing the company's current health and future prospects.
Risk Assessment
Risk Level: medium — As a biotechnology company, Sangamo Therapeutics operates in a highly regulated and competitive industry with inherent risks related to research, development, and commercialization of new therapies.
Key Numbers
- 2025 Q1 — Reporting Period (First quarter of 2025 financial data)
- 2025-03-31 — As of Date (End of the reporting period for financial statements)
- 2024-12-31 — Prior Period End (End of the previous fiscal year for comparative data)
Key Players & Entities
- Sangamo Therapeutics, Inc. (company) — Filer of the 10-Q report
- 20250331 (date) — End of the reporting period
- 20250512 (date) — Filing date of the report
- 501 Canal Blvd. (address) — Company's business and mailing address
- Richmond, CA (location) — City and State of company's address
FAQ
What is the total revenue for Sangamo Therapeutics for the quarter ended March 31, 2025?
The provided text does not contain specific revenue figures for the quarter ended March 31, 2025.
What was Sangamo Therapeutics' net loss for the first quarter of 2025?
The filing text does not specify the net loss for the first quarter of 2025.
What is the company's cash and cash equivalents balance as of March 31, 2025?
Specific figures for cash and cash equivalents as of March 31, 2025, are not detailed in the provided excerpt.
Are there any significant updates on Sangamo's clinical trial programs in this filing?
The provided text is a header and does not contain details on clinical trial programs.
What is the company's fiscal year end date?
Sangamo Therapeutics' fiscal year ends on December 31.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding SANGAMO THERAPEUTICS, INC (SGMO).